[Pharmacological and pharmacodynamic aspects of cancer chemotherapy, with special reference to 5-fluorouracil and its derivatives].
5-FU analogs being investigated in Japan are; 5-FU, FT, FD-1, HCFU, UFT, TAC-278, 5'-DFUR, FF-705, and TK-117. They exert antitumor activity via 5-FU which is an intermediate metabolite of those derivatives. In this paper, UFT, TAC-278, and 5'-DFUR, were particularly investigated from the point of view of pharmacokinetics of those drugs (or 5-FU) in the blood, normal and tumor tissues of patients with gastric cancer. As a result, it is concluded that observation of the sequential changes of 5-FU level in various tissues of humans is potential in designing cancer chemotherapy.
D000971:Antineoplastic Combined Chemotherapy Protocols; D004338:Drug Combinations / Q000378:metabolism; D005467:Floxuridine / Q000378:metabolism; D005472:Fluorouracil / Q000031:analogs & derivatives / Q000378:metabolism*; D006801:Humans; D007700:Kinetics; D009369:Neoplasms / Q000378:metabolism; D005641:Tegafur / Q000378:metabolism; D014498:Uracil / Q000378:metabolism
D004338:Drug Combinations; D005467:Floxuridine; D005641:Tegafur; D014498:Uracil; C036428:TAC 278; D005472:Fluorouracil; C025034:doxifluridine